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Basement membranes (BMs) are sheet-like extracellular matrices that provide essential support to
epithelial tissues. Recent evidence suggests that regulated changes in BM architecture can direct tissue
morphogenesis, but the mechanisms by which cells remodel BMs are largely unknown. The Drosophila
egg chamber is an organ-like structure that transforms from a spherical to an ellipsoidal shape as it
matures. This elongation coincides with a stage-speciﬁc increase in Type IV Collagen (Col IV) levels in the
BM surrounding the egg chamber; however, the mechanisms and morphogenetic relevance of this re-
modeling event have not been established. Here, we identify the Collagen-binding protein SPARC as a
negative regulator of egg chamber elongation, and show that SPARC down-regulation is necessary for the
increase in Col IV levels to occur. We ﬁnd that SPARC interacts with Col IV prior to secretion and propose
that, through this interaction, SPARC blocks the incorporation of newly synthesized Col IV into the BM.
We additionally observe a decrease in Perlecan levels during elongation, and show that Perlecan is a
negative regulator of this process. These data provide mechanistic insight into SPARC's conserved role in
matrix dynamics and demonstrate that regulated changes in BM composition inﬂuence organ mor-
phogenesis.
& 2015 Elsevier Inc. All rights reserved.1. Introduction
Basement membranes (BMs) are sheet-like extracellular ma-
trices that adhere to the basal surfaces of epithelial tissues and
play critical roles in cellular structure, speciﬁcation, organization,
and communication (Yurchenco, 2011). Composed primarily of
Type IV Collagen (Col IV), Laminin, and the heparin sulfate pro-
teoglycan Perlecan, BMs are often assumed to be static support
structures. However, recent evidence suggests that BM structure is
dynamic during development, and that regulated changes in BM
architecture can direct tissue morphogenesis (Daley and Yamada,
2013; Fata et al., 2004; Miner and Yurchenco, 2004; Morrissey and
Sherwood, 2015). Despite these ﬁndings, we know little about how
cells remodel these matrices, or how such changes inﬂuence
morphogenetic outcomes.
The Drosophila egg chamber provides a tractable system to
study the inﬂuence of BM remodeling on morphogenesis (Isabella
and Horne-Badovinac, 2015). Egg chambers are multicellular
structures within the ovary that will each give rise to one egg.netics and Cell Biology, The
60637, USA.
adovinac).They are composed of an interior germ cell cluster and a sur-
rounding somatic epithelium of follicle cells (Fig. 1A). The follicle
cells produce a BM that adheres to the outer surface of the egg
chamber. Egg chamber development proceeds through 14 mor-
phological stages. Between stages 5 and 10, this initially spherical
structure elongates along its anterior–posterior (A–P) axis. This
process depends on a precise organization of the basal epithelial
surface, in which parallel arrays of actin bundles in the follicle cells
and linear, ﬁbril-like aggregates in the BM align perpendicular to
the elongation axis (Cetera and Horne-Badovinac, 2015; Horne-
Badovinac, 2014). The circumferential arrangement of these
structural molecules is thought to act as a “molecular corset” that
constrains egg chamber growth in the direction of alignment,
thereby driving elongation (Fig. 1B) (Gutzeit et al., 1991). Elonga-
tion is also coupled to a collective migration of the follicle cells
along the BM, which causes the egg chamber to rotate within the
matrix and is required for alignment of basal actin bundles and BM
ﬁbrils (Cetera et al., 2014; Haigo and Bilder, 2011).
Two changes in BM architecture coincide with egg chamber
elongation. In addition to the formation of aligned BM ﬁbrils, the
amount of Col IV in the BM doubles between stages 5 and 8 (Haigo
and Bilder, 2011). These stage-speciﬁc remodeling events have
been proposed to promote elongation, as defects in BM integrity or
cell-matrix adhesion inhibit this process (Bateman et al., 2001;
Fig. 1. SPARC down-regulation is necessary for egg chamber elongation.
(A) Egg chamber structure. (B) In the molecular corset model, circumferentially aligned ﬁbrils in the BM constrain egg chamber growth in the direction of alignment. Arrows
indicate direction and relative magnitude of growth. Stage 8. (C) Col IV and SPARC co-localize in the egg chamber BM (arrows). Stage 5, maximum intensity projection. (D–E)
Loss of SPARC immunoﬂuorescence coincides with egg chamber elongation. (D) SPARC immunostained egg chambers. Image represents two stitched micrographs.
(E) Quantiﬁcation of SPARC intensity and aspect ratio. n¼6–12 (SPARC intensity), 10–11 (aspect ratio) egg chambers per data point. Aspect ratio¼ length/width. (F-G)
Persistent SPARC-HA expression with trafﬁc jam-Gal4 inhibits egg chamber elongation. (F–F′) Representative control and SPARC-HA eggs. (G) Persistent SPARC-HA expression
disrupts egg chamber elongation after stage 5. n¼6–30 Egg chambers per data point. (E,G) Data represent mean with s.e.m. Some error bars are too small to be seen. t-test
*¼Po0.05, ***¼Po0.0005. Scale bars: 10 μm (B), 5 μm (C), 50 μm (D,F).
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However, previous experimental manipulations of the BM have
also disrupted other factors required for elongation, such as rota-
tional motion and tissue-level alignment of the basal actin bun-
dles. Because it has so far not been possible to solely manipulate
BM structure, a causal relationship between stage-speciﬁc
BM remodeling and egg chamber elongation remains to be
established.
To determine the relationship between structural changes in
the BM and egg chamber elongation, we sought to identify BM-
associated proteins that regulate these processes. Secreted Protein
Acidic and Rich in Cysteine (SPARC) is a conserved Collagen-
binding protein (Bradshaw, 2009). SPARC mis-regulation perturbs
the function of many extracellular matrices and associated tissues,
and correlates with cancer progression (Clark and Sage, 2008;
Nagaraju et al., 2014). Despite its importance in development and
disease, the mechanism by which SPARC affects BM structure is
uncertain. It has been proposed to regulate Collagen deposition,
degradation, and adhesion to cells, but a coherent view of SPARC
function is lacking (Chlenski et al., 2011; Harris et al., 2011; Mar-
tinek et al., 2008; Pastor-Pareja and Xu, 2011; Sage et al., 1989;
Shahab et al., 2015). SPARC is expressed in early stage follicle cells
and accumulates with Col IV in the BM (Fig. 1C) (Martinek et al.,
2002). Intriguingly, SPARC mRNA disappears from the follicle cells
between stages 5 and 6, coincident with the onset of BM re-
modeling and egg chamber elongation (Martinek et al., 2002).
Here, we show that prolonging the expression of SPARC into
later stages of development inhibits the stage-speciﬁc rise in Col IV
levels within the BM and blocks egg chamber elongation. We
observe that SPARC and Col IV can interact within the secretory
pathway of the follicle cells, and propose a mechanism by which
this interaction inhibits incorporation of newly synthesized Col IV
into the BM. We then directly examine the role of BM protein le-
vels in egg chamber elongation and ﬁnd that increased Col IV and
decreased Perlecan levels both promote elongation, revealing op-
posing effects of these two BM proteins in this system. These
ﬁndings provide new insight into SPARC’s effect on BM structure
and show that regulated changes in BM composition can play
critical roles in organ morphogenesis.2. Materials and methods
2.1. Drosophila genetics
Detailed experimental genotypes are in Table S1. Most crosses
were raised at 25 °C and adult females aged 3 days on yeast at
29 °C; exceptions are in Table S2. Gal4 lines used for UAS transgene
expression are in Table S3. FLP-out expression was induced by
37 °C heat shocks for 1hour, twice daily for 3 days on yeast. vkg-
GFP clones were generated on FRT40A chromosomes using T155-
Gal4 to drive UAS-FLP expression. Most lines were obtained from
the Bloomington Drosophila Stock Center (Bloomington, IN) with
exceptions listed here. vkg-GFP (CC00791), Indy-GFP (CC00377),
Nrg-GFP (G00305) and trol-GFP (CA06698) are from Flytrap
(Buszczak et al., 2007; Morin et al., 2001). UAS-SPARC-HA and UAS-
SPARC-WT are from Portela et al. (2010). UAS-SPARC RNAi (v16678)
and UAS-vkg RNAi (v16986) are from Vienna Drosophila Resource
center (Vienna, Austria). SPARC-Gal4 is from Venken et al. (2011).
trafﬁc jam-Gal4 is from the Drosophila Genetic Resource Center
(Kyoto Institute of Technology, Kyoto, Japan). ubi-nls-mRFP,vkg-GFP,
FRT40A and FRT40A; T155-Gal4, UAS-FLP are from Haigo and Bilder
(2011). trolnull is a gift from S. Haigo, originally from Voigt et al.
(2002). UAS-trol is from Cho et al. (2012).2.2. Staining and microscopy
Ovaries were dissected in S2 medium and ﬁxed for 15 min in
PBSþ0.1% Triton (PBT)þ4% EM-grade formaldehyde (Poly-
sciences), then separated from the muscle sheath by gentle pi-
petting. TRITC-Phalloidin (1:200, Sigma) stains were performed
during ﬁxation. Antibody stains were performed in PBT and de-
tected with Alexa Fluor-conjugated secondary antibodies (1:200,
Invitrogen). With antibody stains, Alexa Fluor 647 Phalloidin (1:50,
Invitrogen) was used to mark actin. Egg chambers were mounted
in SlowFade Antifade (Invitrogen). Antibodies used: rabbit α-HA
(1:200, Rockland), rabbit α-SPARC (1:400) (Martinek et al., 2002),
guinea pig α-laminin (1:400) (Harpaz and Volk, 2012). All images
were obtained using a Zeiss LSM 510 or LSM 880 confocal micro-
scope, except 1 F and S1F, which were obtained with a Leica FluoIII
microscope with Canon rebel camera and 4E, N-P, S1A, and S5A,C-
D, which were obtained using a Leica DM550B microscope with a
Leica DFC425C camera. Image processing and custom image ana-
lysis were performed in ImageJ (see detailed descriptions below).
Graphing and statistical analyses were performed in Prism
(Graphpad).
2.3. Measurements of ﬂuorescence intensity
For SPARC intensity measurements, a representative group of
5–10 follicle cells from central transverse sections of SPARC im-
munostained egg chambers was outlined, and mean intensity
measured. All images were obtained at the same settings.
To measure egg chamber BM Col IV-GFP and Pcan-GFP in-
tensity, a confocal section through the plane of the BM was ac-
quired. Mean intensity of the brightest region was measured. All
images were obtained at the same settings.
For the anterior-posterior Col IV-GFP and eGFP intensity mea-
surements in mirror-Gal4 egg chambers, 5 pixel wide (Col IV-GFP)
or 10 pixel wide (eGFP) lines were drawn over the BM (Col IV-GFP)
or follicle cells (eGFP) in central transverse sections from the
anterior to posterior tip, straightened, and segmented into 21
equal regions (Fig. S2E). The 11 odd-numbered regions were la-
beled from 0 (anterior tip) to 100 (posterior tip) in increments of
10, and mean GFP intensity of each region was measured. All
images were obtained at the same settings.
For Laminin immunoﬂuorescence intensity measurements,
control and SPARC-HA-expressing egg chambers were stained in
the same tube with α-Laminin and α-SPARC to differentiate be-
tween conditions. Laminin intensity was measured as described
above for Col IV-GFP and Pcan-GFP.
2.4. Measurement of follicle cell migration rates
For follicle cell migration rates, 20–30 min time-lapse movies
were acquired from Neuroglian-GFP and Indy-GFP-expressing egg
chambers. Live imaging of follicle cell migration was performed as
previously described (Lerner et al., 2013). The leading edge of a
single follicle cell was marked at the start and end of the movie
and distance traveled was measured and divided by movie length
(minutes). Two distant cells were measured and their rates aver-
aged for each egg chamber.
2.5. Measurement of egg chamber aspect ratios
For aspect ratio measurements, in central transverse sections
egg chamber length (anterior to posterior tip) and width (widest
region perpendicular to anterior–posterior axis) were measured,
and ratio of length:width was calculated.
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Images of basal actin bundles were acquired in ﬁxed, phalloi-
din-stained egg chambers. To determine the average orientation of
the actin bundles within each cell, a circular region of interest
(ROI) was manually drawn over each cell to include basal actin
bundles but exclude cell boundaries and orientation of each ROI
was determined using the “Measure” feature of the OrientationJ
plugin in ImageJ (Rezakhaniha et al., 2012). The tissue-level
alignment (“order parameter”) was calculated as previously de-
scribed (Cetera et al., 2014) using a custom Python script.
2.7. Measurement of the length and tissue-level alignment of BM
ﬁbrils
Confocal sections through the plane of the BM were acquired in
ﬁxed, Col IV-GFP egg chambers. BM ﬁbrils were isolated via two
sequential thresholding steps: ﬁrst an intensity threshold to re-
move the dimmest 95% of pixels, followed by a step to remove
objects with an area of o0.38 μm2 and circularity 40.35 using
the “Analyze Particles” tool in ImageJ. Length (feret's diameter)
and orientation (feret's angle) were calculated for each ﬁbril using
the “Analyze Particles” tool. The ﬁbril order parameter was cal-
culated as described above for basal actin bundles using the or-
ientation of each ﬁbril rather than the average orientation of each
cell.
2.8. Co-immunoprecipitation and western blotting
Adult females were aged 3 days on yeast at 25 °C and dissected
in S2 media. Ovaries from 25 females per genotype were collected
and lysed in cold modiﬁed RIPA buffer (50 mM Tris pH 7.8, 100 mM
NaCl, 2 mM CaCl2, 0.1% SDS, 0.5% Sodium Deoxycholate, 1%
triton)þcomplete protease inhibitor cocktail (Roche) by manual
grinding and passage through a 27-gauge needle. Lysate was
centrifuged at 13,000 RPM and supernatant collected. GFP im-
munoprecipitation reactions were performed using GFP-Trap
beads (Chromotek) at 4 °C overnight. Input lysate and im-
munoprecipitate were analyzed via Western Blot on a 4–15% Mini-
PROTEAN TGX Gel (Bio-Rad) using the following antibodies: rabbit
α-SPARC (1:1500) (Martinek et al., 2002), chicken α-GFP
(1:10,000, abcam). IRDye (LI-COR) secondary antibodies were used
at 1:5000. Blots were imaged with Odyssey software version 2.1
(LI-COR Biosciences).
2.9. In situ hybridization
In situ hybridization for the Cg25C transcript was performed as
previously described (Lerner et al., 2013) with the following
modiﬁcation: a gurken probe was included in addition to the
Cg25C probe to ensure probe penetrance into germ cells. Primers
used for gurken probe production (underlined text indicates
position of T7 promoter sequence): F: CAGCAGCAGATCCAGGAGAC,
R: TAATACGACTCACTATAGGGCGCTCTCCATCGTAGTCGTT.3. Results
3.1. SPARC down-regulation is necessary for egg chamber elongation
The conspicuous timing of SPARCmRNA down-regulation at the
onset of egg chamber elongation led us to investigate whether this
event is required for morphogenesis. We ﬁrst conﬁrmed that, like
the mRNA, SPARC protein disappears from the follicle cells be-
tween stages 5 and 7 (Fig. 1D and E). We then used the trafﬁc jam-
Gal4 driver, which is expressed in the follicle cells at all stages, toprolong SPARC expression. Importantly, expression of either a HA-
tagged UAS-SPARC transgene (SPARC-HA) or an untagged UAS-
SPARC transgene (SPARC-WT) with trafﬁc jam-Gal4 inhibits egg
chamber elongation (Fig. 1F and G, S1A). This defect is ﬁrst seen at
stage 6, consistent with when SPARC is normally lost (Fig. 1G). The
levels of persistent SPARC expression into later stages of devel-
opment are equivalent to those of the endogenous protein at stage
5 (Fig. S1B–C). Moreover, failure to elongate is caused speciﬁcally
by expression of SPARC beyond stage 5, as SPARC-HA expression
using a SPARC-Gal4 driver has no effect (Fig. S1D). Collectively,
these results indicate that down-regulation of SPARC expression is
necessary for egg chamber elongation.
3.2. SPARC negatively regulates Col IV levels in the BM
We next explored why egg chamber elongation is incompatible
with SPARC expression. Because SPARC down-regulation correlates
with BM remodeling, we hypothesized that SPARC might disrupt this
process. Using a GFP protein trap in the Col IV-α2 gene viking (Col IV-
GFP), we noticed a consistently dimmer Col IV-GFP signal in the BMs
of SPARC-HA egg chambers compared to controls. Quantiﬁcation of
Col IV-GFP levels revealed that the increased accumulation of Col IV
in the BM that normally begins at stage 5 is largely eliminated by
prolonged SPARC-HA expression (Fig. 2A). This drop in Col IV levels is
not due to a loss of Laminin, as Laminin levels are unchanged by
persistent SPARC expression (Fig. S2A). In contrast, SPARC-HA ex-
pression does not block formation or alignment of BM ﬁbrils (Fig. 2B
and C, S2B–C). Although the decrease in Col IV levels likely does af-
fect ﬁbril structure to some extent, their overall persistence in the
SPARC-HA condition suggests that a mechanism independent of the
increase in Col IV levels governs their formation. Two other factors
required for elongation-tissue-level alignment of basal actin bundles
and egg chamber rotation-are also normal (Fig. 2D–H, S2D, Supple-
mentary movie 1). These data indicate that SPARC down-regulation is
necessary for the increase in BM Col IV levels that coincides with egg
chamber elongation.
Interestingly, by expressing SPARC-HA with the mirror-Gal4
driver, which is restricted to the central region of the follicular
epithelium (Fig. 2I), we found that the BM associated with SPARC-
HA-expressing cells exhibits decreased Col IV levels, whereas the
BM at the poles is unaffected (Fig. 2J–L, S2E). Therefore, the effect
of SPARC activity appears to be restricted to the BM immediately
adjacent to SPARC-HA-expressing cells.
We have observed no defects resulting from the loss of SPARC
function in the egg chamber. The populations of SPARC protein
within the follicle cells and in the BM are both effectively depleted
by RNAi (Fig. S3A–C). Yet, the loss of SPARC has no effect on either
the intracellular or extracellular populations of Col IV, or on the
shape of the egg (Fig. S3D–G). These data suggest that SPARC may
have a Col IV-independent function during the early stages of egg
chamber development, as has been seen in other Drosophila tis-
sues (Portela et al., 2010).
3.3. SPARC and Col IV interact within the secretory pathway
We next sought to clarify how persistent SPARC-HA expression
reduces Col IV levels in the follicular BM. One possibility is that
SPARC inhibits Col IV production or secretion. However, we observe
no obvious defects in Col IV transcription, translation or exocytosis
under persistent SPARC expression (Fig. S4A–C). Alternatively, recent
work has suggested that SPARC may promote solubility of Col IV in
the extracellular space (Pastor-Pareja and Xu, 2011; Shahab et al.,
2015). In Drosophila larvae, Col IV is produced by the fat body and
then distributed, via the hemolymph, to organs throughout the body.
The fat body itself is surrounded by a BM; thus, the Col IV produced
by this organ must remain soluble in order to pass through this BM
Fig. 2. SPARC negatively regulates basement membrane Col IV levels.
(A) SPARC-HA expression with trafﬁc jam-Gal4 decreases Col IV-GFP intensity in the BM, largely blocking the increase in Col IV levels normally seen during elongation stages.
n¼4–20 egg chambers per data point. (B–C) SPARC-HA expression does not block BM ﬁbril formation or alignment. (D-E) SPARC-HA expression does not alter tissue-level
alignment of basal actin bundles. (F–H) SPARC-HA expression does not alter follicle cell migration rates. (F) Quantiﬁcation of cell migration rates. (G–H) Still images of follicle
cell migration from supplementary movie 1. Yellow outlines highlight movement of the same group of cells over time. (I) The mirror-Gal4 driver expresses UAS-eGFP in a
central region of the follicular epithelium. (J–L) SPARC-HA expression locally decreases Col IV-GFP levels. (J–J′) mirror-Gal4, SPARC-HA egg chamber showing SPARC-HA
expression pattern and adjacent BM. Col IV-GFP intensity is decreased adjacent to SPARC-HA-expressing cells (bracketed region) relative to non-expressing cells at the poles
(arrowheads). (K) Quantiﬁcation of UAS-eGFP levels along the A–P axis in mirror-Gal4 indicates mirror expression domain. n¼14 egg chambers per condition. (L) Col IV-GFP
intensity in the BM along the A–P axis in control andmirror-Gal4, UAS-SPARC-HA. SPARC-HA decreases Col IV levels speciﬁcally in themirror expression domain. n¼16–21 egg
chambers per condition. (K–L) 0 represents anterior pole, 100 represents posterior pole. Dotted lines delineate the mirror expression domain. (B–L) Stage 8. (A, F, K, L) Data
represent mean with s.e.m. Some error bars are too small to be seen. t-test *¼Po0.05, **¼Po0.005, ***¼Po0.0005. Scale bars: 5 μm (B-E, G-H), 15 μm (I–J).
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to accumulate around fat body cells in a cell-autonomous manner
(Pastor-Pareja and Xu, 2011; Shahab et al., 2015). In contrast, Col IV
produced by the follicle cells is meant to integrate into the adjacent
BM immediately upon secretion. We therefore reasoned that per-
sistent SPARC-HA expression in the follicle cells might aberrantly
solubilize Col IV, causing it to diffuse through the existing matrix
rather than adhere.
For SPARC to efﬁciently perform this solubilizing function, it
would likely have to bind to Col IV either before or very shortly
after it exits the cell and encounters the BM. Such an interactionwould also explain the observed local effect of persistent SPARC
expression (Fig. 2J–L). We therefore investigated whether these
two proteins form a complex within the secretory pathway. We
ﬁrst examined whether SPARC and Col IV co-localize within the
follicle cells. To distinguish between exocytic and endocytic po-
pulations, we performed this analysis in epithelia mosaic for Col
IV-GFP expression. SPARC and Col IV-GFP strongly co-localize only
within Col IV-GFP-expressing cells, indicating co-localization
within the secretory pathway (Fig. 3A).
To further explore SPARC’s intracellular association with Col IV,
we examined SPARC localization under two conditions that alter
Video S1. Supplementary Movie 1. ProlongedSPARCexpression does not alter egg chamber rotation dynamics. 20 minute time-lapse movie of stage 8 follicle cell
migration in control (left) and tj- Gal4;SPARC-HA (right) egg chambers. Cell membranes are marked with Neuroglian-GFP and Indy-GFP. Scale: 5 μm.Supplementary material
related to this article can be found online at http://dx.doi.org/10.1016/j.ydbio.2015.08.018.
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exchange factor Crag (Calmodulin-binding protein related to a Rab3
GDP/GTP exchange protein), which directs Col IV secretion to the
basal epithelial surface (Denef et al., 2008; Lerner et al., 2013).
RNAi knockdown of Crag causes both Col IV and SPARC to be
aberrantly trafﬁcked to the apical surface, where they co-localize
(Fig. 3B and C). Second, we manipulated prolyl-4-hydroxylase-alpha
EFB (PH4), an enzyme necessary for Col IV folding in the ER (Lerner
et al., 2013; Myllyharju and Kivirikko, 2004; Pastor-Pareja and Xu,
2011). RNAi knockdown of PH4 causes SPARC to accumulate with
Col IV in large punctae within the ER (Fig. 3B and D). Signiﬁcantly,
although SPARC is normally lost from follicle cells by stage 8, the
SPARC that is trapped in the ER under PH4 depletion persists into
this stage (Fig. 3E and F). This signal likely represents a SPARC
population that has been aberrantly retained in the ER due to
physical association with trapped Col IV.
Finally, we observed, via co-immunoprecipitation from whole
ovary extract, that Col IV and SPARC physically interact in the
follicle cells (Fig. 3G). The protein observed in this experiment
likely represents the intracellular population, as extracellular Col
IV in the BM is insoluble and cannot be pulled down in this assay.
Together, these data suggest that SPARC binds to and transits the
secretory pathway with Col IV, and we propose that this interac-
tion inhibits incorporation of newly secreted Col IV into the BM.
3.4. Col IV and Perlecan have opposing effects on egg chamber
elongation
We have found that prolonged SPARC expression in the folli-
cular epithelium causes two phenotypes: a decrease in BM Col IV
levels and a defect in egg chamber elongation. It is known that
complete loss of Col IV from the BM inhibits elongation (Haigo and
Bilder, 2011); however, the observations above led us to ask
whether a reduction in Col IV levels is also sufﬁcient to cause this
defect. To this end, we directly manipulated Col IV levels by ex-
pressing an RNAi transgene against viking (vkg RNAi) in the follicle
cells. Because Gal4 activity is temperature-sensitive, maintaining
the experimental crosses at 18 °C allowed us to modulate vkg RNAi
activity to produce BM Col IV levels similar to those observed upon
SPARC-HA expression (Fig. 4A–D). We found that this vkg RNAi
condition blocks elongation similarly to SPARC-HA (Fig. 4E). No-
tably, reduced temperature alone does not alter elongation (Fig.
S5A). Thus, a reduction in BM Col IV levels is sufﬁcient to disrupt
egg chamber elongation, and likely explains why persistent SPARCexpression causes this defect.
Intriguingly, closer examination of these data revealed an un-
expected result. Although our vkg RNAi condition leads to slightly
lower levels of Col IV than SPARC-HA, the elongation defect is less
severe than in SPARC-HA (Fig. 4D and E). This observation suggests
that some other elongation factor is differentially affected by these
two conditions. Perlecan is a likely candidate, as its presence in the
BM is partially dependent on Col IV (Haigo and Bilder, 2011; Pas-
tor-Pareja and Xu, 2011). In Drosophila, the gene encoding Perlecan
is called terribly reduced optic lobes (trol). Using a GFP protein trap
in this gene (Pcan-GFP), we observed a strong decrease in Perlecan
levels in the vkg RNAi condition; in contrast, SPARC-HA expression
only weakly affects Perlecan levels (Fig. 4F–I). These data raise the
possibility that the level of Perlecan in the BM is also an important
factor regulating egg chamber elongation.
The role of Perlecan in egg chamber elongation has not been
previously examined. In the Drosophila wing disc, however, Col IV
and Perlecan have been shown to confer opposing physical char-
acteristics to the BM – Col IV promotes BM constriction, whereas
Perlecan counters this force (Pastor-Pareja and Xu, 2011). We
therefore hypothesized that decreasing Perlecan levels would have
an effect equivalent to increasing Col IV levels, promoting egg
chamber elongation by enhancing the constrictive force of the
molecular corset.
Consistent with our hypothesis, we found that Perlecan levels
decrease during elongation stages in wild-type egg chambers
(Fig. 4J–M). Moreover, over-expression of Perlecan with a UAS-trol
transgene signiﬁcantly inhibits elongation (Fig. 4N). This result
suggests that the natural decrease in Perlecan may be required for
egg chamber elongation.
To further test how Perlecan affects elongation, we depleted
this protein with RNAi. Monitoring BM levels of the Pcan-GFP
protein trap conﬁrmed efﬁcient knockdown in all cases (Fig. S5B).
Strong depletion of Perlecanwith trol RNAi inhibits elongation (Fig.
S5C). We also examined partial knockdown of Perlecan and found
that this condition increases elongation (Fig. 4O). We ﬁrst saw this
phenotype by expressing RNAi against GFP (GFP RNAi) in Pcan-GFP
heterozygotes (Fig. 4O), and conﬁrmed this effect in egg chambers
heterozygous for a null mutation in trol (Fig. S5D). Altogether,
these data show that differences in the levels of Perlecan can re-
sult in different outcomes with respect to egg chamber elongation.
Finally, the results of the over-expression and partial knock-
down experiments above suggest that a stronger decrease in
Perlecan levels may explain why the elongation defect in our vkg
Fig. 3. SPARC associates with Col IV in the secretory pathway. (A–A″) In a Col IV-GFP mosaic epithelium, SPARC co-localizes with Col IV-GFP in expressing cells (arrows) but
not in non-expressing cells (arrowheads), indicating co-localization within the secretory pathway. Dashed lines outline 3 cells not expressing Col IV-GFP. Stage 8. (B) Wild-
type Col IV and SPARC localization at stage 3. SPARC is in the BM and intracellular punctae. (C) In Crag RNAi epithelia, Col IV and SPARC are mis-trafﬁcked to the apical surface
(arrows). (D) In PH4 RNAi epithelia, SPARC accumulates with Col IV in distended ER cisternae (arrows). (E) Wild-type Col IV and SPARC localization at stage 8. SPARC is no
longer observed within cells and its BM localization is strongly reduced. (F) In PH4 RNAi epithelia, SPARC that is trapped in the ER persists beyond the stage when it is
normally cleared from follicle cells (arrows). (G) GFP pulldown from ovaries can co-immunoprecipitate SPARC in the presence, but not in the absence, of Col IV-GFP. IP: GFP,
Blot: GFP & SPARC. Scale bars: 5 μm (A–F).
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Fig. 4. Importance of Col IV and Perlecan levels for egg chamber elongation. (A–D) 18 °C vkg RNAi expression reduces Col IV-GFP levels in the BM similarly to SPARC-HA
expression. (A–C) Representative images of Col IV-GFP in the BM at stage 8. (D) Quantiﬁcation of BM Col IV-GFP intensity. Asterisks indicate signiﬁcance relative to SPARC-HA.
n¼4–10 egg chambers per data point. (E) 18 °C vkg RNAi expression mostly recapitulates the effect of SPARC-HA expression on egg chamber elongation. (F–I) SPARC-HA
expression modestly decreases Pcan-GFP intensity in the BM, while 18 °C vkg RNAi strongly decreases Pcan-GFP intensity. (F-H) Representative images of Pcan-GFP in the BM
at stage 8. (I) Quantiﬁcation of BM Pcan-GFP intensity. n¼14–15 egg chambers per data point. Asterisks indicate signiﬁcance relative to control. (J–M) Pcan-GFP levels in the
BM decrease during elongation in wild-type egg chambers. (J–L) Representative images of Pcan-GFP in the BM. (M) Quantiﬁcation of BM Pcan-GFP intensity. n¼10 egg
chambers per stage. (N) Perlecan overexpression with UAS-trol inhibits egg chamber elongation. (O) 50% Perlecan knockdown via GFP RNAi expression in Pcan-GFP het-
erozygotes enhances egg chamber elongation. (P) 50% Perlecan knockdown via GFP RNAi in Pcan-GFP heterozygotes increases elongation in a control background and
partially rescues the SPARC-HA elongation defect. (E, N-P) Stage 14. (D–E, I, M–P) Data represent mean with s.e.m. Some error bars are too small to be seen. t-test n¼Po0.05,
nn¼Po0.005, nnn¼Po0.0005. Scale bars: 10 μm (A–C, F–H, J–L).
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A.J. Isabella, S. Horne-Badovinac / Developmental Biology 406 (2015) 212–221220RNAi condition is less severe than that of SPARC-HA. In this case,
further reducing Perlecan levels under SPARC-HA should mitigate
the elongation defect seen in this background. To test this idea
directly, we expressed both SPARC-HA and GFP RNAi in Pcan-GFP
heterozygotes. As expected, decreasing Perlecan levels partially
rescues the elongation defect caused by SPARC-HA alone (Fig. 4P).
Altogether, these data reveal that Col IV promotes egg chamber
elongation, while Perlecan inhibits this process.4. Discussion
Here we show that dynamic regulation of two BM proteins is
necessary for Drosophila egg chamber elongation. We observe that
a stage-speciﬁc increase in Col IV levels promotes elongation, and
that SPARC must be down-regulated for this increase to occur. We
further show that SPARC can associate with Col IV within the se-
cretory pathway, and propose that this interaction blocks its in-
corporation into the BM. Finally, we observe that Perlecan levels
decrease in the BM during egg chamber elongation, and ﬁnd that
lower Perlecan levels promote this process. Collectively, these data
reveal a precise regulatory program to modulate egg chamber
elongation through the control of BM protein levels (Fig. 5).
Our work offers new insight into the relationship between
SPARC and Col IV. SPARC is expressed in the follicle cells during
early stages of egg chamber development. Although the function
of SPARC during these stages is not yet clear, we have found that it
must be down-regulated for Col IV levels to increase in the BMFig. 5. Model for the regulation of BM protein levels during egg chamber elonga-
tion.
Summary of BM protein dynamics during egg chamber development. Top: sche-
matic of egg chamber development representing round (stg. 1–4) and elongating
(stg. 6–8) egg chambers. Numbers indicate stage. Bottom: SPARC and Perlecan le-
vels decrease, and Collagen IV levels increase, in a stage-speciﬁc manner to pro-
mote egg chamber elongation. Gray dotted line indicates onset of elongation.during egg chamber elongation. Our data do not exclude the
possibility that SPARC promotes the removal of Col IV from the
existing BM scaffold. However, given the previous evidence in
Drosophila that SPARC enhances Col IV solubility (Pastor-Pareja
and Xu, 2011; Shahab et al., 2015), we favor a model in which
persistent SPARC expression aberrantly solubilizes Col IV and
blocks its incorporation into the follicular BM.
It is likely that Col IV rapidly becomes insoluble upon secretion
due to immediate access to cellular receptors and other BM mo-
lecules. We have now shown that SPARC can associate with Col IV
while the two proteins are still within the secretory pathway. This
intracellular interaction may be important in tissues like the fat
body where Col IV must maintain solubility to diffuse to distant
tissues. In the follicle cells, however, Col IV is meant to adhere to
the BM immediately upon secretion. We therefore propose that
the association between SPARC and Col IV in this tissue is detri-
mental, necessitating the observed down-regulation of SPARC.
This work also demonstrates the need for precise BM re-
modeling during egg chamber elongation. Two BM remodeling
events – formation of aligned ﬁbrils and increased Col IV levels –
have been shown to correlate with the onset of egg chamber
elongation (Haigo and Bilder, 2011). We have now found that the
stage-speciﬁc increase in Col IV levels is required for this process.
Importantly, persistent SPARC expression is the ﬁrst condition that
changes the structure of the follicular BM without also affecting
the cellular processes known to be required for elongation, such as
egg chamber rotation and tissue-level alignment of the basal actin
bundles. This work therefore provides direct evidence that stage-
speciﬁc remodeling of the BM promotes egg chamber elongation.
Given that Col IV provides tensile strength to BMs, its increase is
likely necessary for the molecular corset to properly constrain the
growing tissue. We expect that the aligned BM ﬁbrils contribute
anisotropy to this constraining force, although future work is
needed to conﬁrm their role.
We additionally identify a role for Perlecan in controlling egg
chamber elongation. Our data indicate that a low level of Perlecan
in the BM maximally promotes elongation, whereas either higher
levels or a complete loss inhibit this process. Although it is not yet
clear why a complete loss of Perlecan blocks elongation, the
phenotypes induced by moderate changes in Perlecan levels could
be explained by this protein’s effect on the physical properties of
the BM. Perlecan has been proposed to promote BM elasticity and
counter the constrictive force exerted by Col IV (Pastor-Pareja and
Xu, 2011). Hyper-elasticity of a BM containing high levels of Per-
lecan may weaken the constraining force of the corset. In support
of this notion, we have found a stage-speciﬁc decrease of Perlecan
levels in the follicular BM that appears to contribute to elongation.
An additional mechanism, therefore, may exist to control Perlecan
levels during this process.
We and others have observed that Perlecan levels in the BM
often depend on Col IV (Haigo and Bilder, 2011; Pastor-Pareja and
Xu, 2011). While co-regulation of these opposing factors may help
to buffer the physical properties of the BM against variations in Col
IV expression, it creates a challenge in situations requiring in-
dependent regulation of Col IV levels. Therefore, it is intriguing
that SPARC-HA expression, unlike vkg RNAi, decreases Col IV levels
with only a minimal effect on Perlecan. This suggests that, in some
cases, SPARC may provide a valuable mechanism to uncouple these
proteins and allow for speciﬁc regulation of Col IV levels. The
difference between these conditions also offers insight into the
relationship between Col IV and Perlecan. In vkg RNAi, Col IV
protein is not produced. In contrast, under SPARC-HA expression
Col IV appears to be both produced and secreted, but fails to be
incorporated into the BM. Thus, our data suggest that Col IV may
facilitate Perlecan secretion, but not its subsequent incorporation
into the BM once outside the cell.
A.J. Isabella, S. Horne-Badovinac / Developmental Biology 406 (2015) 212–221 221Altogether, this study highlights how regulated changes in BM
protein levels can play a central role in organ morphogenesis.Funding
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